Cognyte Software Ltd. (NASDAQ:CGNT) Insider Acquires $2,621,052.00 in Stock

Cognyte Software Ltd. (NASDAQ:CGNT) insider Topline Capital Management, Ll purchased 416,040 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $6.30 per share, with a total value of $2,621,052.00. Following the purchase, the insider now owns 9,020,184 shares in the company, valued at approximately $56,827,159.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Cognyte Software Stock Performance

CGNT opened at $6.31 on Friday. Cognyte Software Ltd. has a twelve month low of $4.00 and a twelve month high of $8.70. The business has a 50 day moving average price of $7.40 and a 200 day moving average price of $7.49.

Cognyte Software (NASDAQ:CGNT) last issued its quarterly earnings results on Tuesday, September 10th. The medical device company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.07. Cognyte Software had a negative return on equity of 2.56% and a negative net margin of 1.35%. The company had revenue of $84.40 million during the quarter, compared to analyst estimates of $83.69 million. During the same period in the previous year, the company earned ($0.11) earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, research analysts expect that Cognyte Software Ltd. will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Cognyte Software by 91.4% in the second quarter. Signaturefd LLC now owns 3,311 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 1,581 shares in the last quarter. Legacy Advisors LLC grew its position in Cognyte Software by 1.4% in the second quarter. Legacy Advisors LLC now owns 143,790 shares of the medical device company’s stock valued at $1,099,000 after acquiring an additional 2,041 shares during the period. nVerses Capital LLC bought a new stake in Cognyte Software in the second quarter valued at $28,000. Essex Investment Management Co. LLC grew its position in Cognyte Software by 1.6% in the first quarter. Essex Investment Management Co. LLC now owns 339,452 shares of the medical device company’s stock valued at $2,807,000 after acquiring an additional 5,244 shares during the period. Finally, Hillsdale Investment Management Inc. grew its position in Cognyte Software by 32.8% in the fourth quarter. Hillsdale Investment Management Inc. now owns 28,339 shares of the medical device company’s stock valued at $182,000 after acquiring an additional 7,000 shares during the period. 72.92% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on CGNT. Wedbush boosted their price target on Cognyte Software from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, June 20th. StockNews.com cut Cognyte Software from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Needham & Company LLC restated a “hold” rating on shares of Cognyte Software in a report on Tuesday.

About Cognyte Software

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.